-

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024.

Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Thursday, February 6, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time.

Three options for joining the conference call

Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts

Dial-in by phone
U.S.: +1 646 828 8193
UK: +44 (0)330 165 4027
GER: +49 (0)69 6610 2480
Conference ID: 9237018
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

Access the audio webcast - Click here: Access Webcast

A conference call replay will be available by using the following link:
https://event.webcasts.com/starthere.jsp?ei=1684130&tp_key=c56f1d6ba2

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.

Source: QIAGEN N.V.

Category: Financial

Contacts

John Gilardi
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+49 152 018 11711
+1 240 686 2222
Email: ir@qiagen.com

Domenica Martorana
Associate Director Investor Relations
+49 2103 29 11244
+49 152 018 11244
Email: ir@qiagen.com

QIAGEN N.V.

NYSE:QGEN
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)

Release Versions

Contacts

John Gilardi
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711
+49 152 018 11711
+1 240 686 2222
Email: ir@qiagen.com

Domenica Martorana
Associate Director Investor Relations
+49 2103 29 11244
+49 152 018 11244
Email: ir@qiagen.com

More News From QIAGEN N.V.

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split. QIAGEN announced in November 2025 plans for the repurchase, which comes after QIAGEN has returned about $650 million to shareholders since the start of 2024 through a synthetic...

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston. The first public introduction of QIAsymphony Connect builds on more than 3,000 cumulative placements at the end of 2024 of the first-generation v...

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability targets. QIAGEN reaffirmed its FY 2025 outlook for net sales growth of about 4-5% CER (about 5-6% CER core sales excluding divestments) and raised its adjusted diluted EPS target to about $2.38 CER (previously about $2.35 CER). QIAGEN also expects an adjusted opera...
Back to Newsroom